Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

UBS Initiates Coverage On Bio-Rad Laboratories with Buy Rating, Announces Price Target of $395

Author: Benzinga Newsdesk | December 07, 2023 07:10am
UBS analyst Dan Leonard initiates coverage on Bio-Rad Laboratories (NYSE:BIO) with a Buy rating and announces Price Target of $395.

Posted In: BIO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist